Page 29 - Read Online

Page 8 of 11 Raza et al. Hepatoma Res 2019;5:42 I http://dx.doi.org/10.20517/2394-5079.2019.014

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al.; Global Burden of Disease Liver Cancer Collaboration. The burden
of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global
burden of disease study 2015. JAMA Oncol 2017;3:1683-91.
2. Blonski W, Kotlyar DS, Forde KA. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol 2010;16:3603-15.
3. Bertot LC, Adams LA. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol
2019;13:179-87.
4. Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, et al. The global obesity pandemic: shaped by global drivers and local
environments. Lancet 2011;378:804-14.
5. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors
and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11-20.
6. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, et al. Body-mass index and risk of 22 specific cancers: a population-
based cohort study of 5.24 million UK adults. Lancet 2014;384:755-65.
7. Milic S, Lulic D, Stimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J
Gastroenterol 2014;20:9330-7.
8. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol 2017;67:862-73.
9. Petrucciani N, Gugenheim J. Molecular pathways between obesity, non-alcoholic steatohepatitis (NASH) and hepatocellular
carcinoma (HCC). Hepatobiliary Surg Nutr 2019;8:395-7.
10. Xia MF, Bian H, Gao X. NAFLD and diabetes: two sides of the same coin? Rationale for gene-based personalized NAFLD treatment.
Front Pharmacol 2019;10:877.
11. Masarone M, Rosato V, Aglitti A, Bucci T, Caruso R, et al. Liver biopsy in type 2 diabetes mellitus: steatohepatitis represents the sole
feature of liver damage. PLoS One 2017;12:e0178473.
12. Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action. Diabetes Care
2017;40:419-30.
13. Mantovani A, Targher G. Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease.
Ann Transl Med 2017;5:270.
14. Agosti P, Sabba C, Mazzocca A. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver
microenvironment. Biochim Biophys Acta Mol Basis Dis 2018;1864:607-17.
15. Yang JD, Ahmed F, Mara KC, Addissie BD, Allen AM, et al. Diabetes is associated with increased risk of hepatocellular carcinoma in
cirrhosis patients with nonalcoholic fatty liver disease. Hepatology 2019; Epub ahead of print. doi: 10.1002/hep.30858
16. Margini C, Dufour JF. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Liver Int
2016;36:317-24.
17. Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, et al. Nonalcoholic steatohepatitis is the fastest growing cause of
hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol 2019;17:748-55.e3.
18. Reig M, Gambato M, Man NK, Roberts JP, Victor D, et al. Should patients with NAFLD/NASH be surveyed for HCC? Transplantation
2019;103:39-44.
19. Sadler EM, Mehta N, Bhat M, Ghanekar A, Greig PD, et al. Liver transplantation for NASH-related hepatocellular carcinoma versus
non-NASH etiologies of hepatocellular carcinoma. Transplantation 2018;102:640-7.
20. Olofson AM, Gonzalo DH, Chang M, Liu X. Steatohepatitic variant of hepatocellular carcinoma: a focused review. Gastroenterology
Res 2018;11:391-6.
21. Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, et al. Risk of hepatocellular cancer in patients with non-alcoholic
fatty liver disease. Gastroenterology 2018;155:1828-37.e2.
22. Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, et al. Modeling NAFLD disease burden in China, France, Germany,
Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 2018;69:896-904.
23. Uygun A. Is that possible to stop or cease the NASH to turn into HCC? J Gastrointest Cancer 2017;48:250-5.
24. Yopp AC, Choti MA. Non-alcoholic steatohepatitis-related hepatocellular carcinoma: a growing epidemic? Dig Dis 2015;33:642-7.
25. Weinmann A, Alt Y, Koch S, Nelles C, Duber C, et al. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular
carcinoma. BMC Cancer 2015;15:210.
26. Oda K, Uto H, Mawatari S, Ido A. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a
review of human studies. Clin J Gastroenterol 2015;8:1-9.
27. Page JM, Harrison SA. NASH and HCC. Clin Liver Dis 2009;13:631-47.
28. Zen Y, Katayanagi K, Tsuneyama K, Harada K, Araki I, et al. Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol
Int 2001;51:127-31.
29. Gawrieh S, Dakhoul L, Miller E, Scanga A, deLemos A, et al. Characteristics, aetiologies and trends of hepatocellular carcinoma in
patients without cirrhosis: a United States multicentre study. Aliment Pharmacol Ther 2019;50:809-21.